News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NovaBay Pharmaceuticals, Inc. (NBY) Supports Legislation to Attack Antibiotic Resistance


6/17/2013 8:49:50 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EMERYVILLE, Calif., June 17, 2013 (GLOBE NEWSWIRE) -- Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) today announced NovaBay's support for legislation by U.S. Rep. Jim Matheson (D-UT) to attack the growing crisis of antibiotic resistance. NovaBay is a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary AganocidesĀ®.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES